@article{3020119,
    title = "Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?",
    author = "Katsoulis, K. and Kipourou, M. and Loukides, S.",
    journal = "Expert Opinion on Biological Therapy",
    year = "2022",
    volume = "22",
    number = "3",
    pages = "377-384",
    publisher = "Taylor and Francis Ltd.",
    issn = "1471-2598, 1744-7682",
    doi = "10.1080/14712598.2021.1960977",
    abstract = "Introduction: Eosinophils play a central role in the inflammation of asthma and are the target of new biologic treatments for patients with severe asthma. Biologics targeting the IL-5 pathway have been shown to reduce asthma exacerbations, improve lung function, reduce oral corticosteroid use, and improve quality of life, accompanied by reduced or even eliminated blood eosinophils. Eosinophils have been associated with host protection and tumor growth, raising potential concerns about the consequences of these long-term therapies that reduce or eliminate them. Areas covered: In this review, we explore the current safety profile of biologics regarding the impact they may have on blood eosinophils, trying to answer the question about any safety consideration. Expert opinion: Eosinophils have been associated with host protection and tumor growth, raising potential concerns about the consequences of long-term therapies that reduce or eliminate these blood cells. © 2021 Informa UK Limited, trading as Taylor & Francis Group."
}